Rational design of therapeutic siRNAs: Minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease

Molecular Therapy

Volumn 19, Issue 12, 2011, Pages 2169-2177

  Boudreau, Ryan L ^a   Spengler, Ryan M ^b   Davidson, Beverly L ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL MICRORNA; MICRORNA; NUCLEOTIDE; PARVOVIRUS VECTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG DESIGN; DRUG SAFETY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; NONHUMAN; OFF TARGET GENE SILENCING; RNA BINDING; RNA INTERFERENCE; RNA SEQUENCE; RNA TRANSLATION; TRANSLATION REPRESSION;

EID: 82955233704     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.185     Document Type: Article

References (41)

1. Provost, P, Dishart, D, Doucet, J, Frendewey, D, Samuelsson, B and Rådmark, O (2002). Ribonuclease activity and RNA binding of recombinant human Dicer. EMBO J 21:5864-5874. (Pubitemid 35315284)
2. Krol, J, Loedige, I and Filipowicz, W (2010). The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11:597-610.
3. Lee, Y, Ahn, C, Han, J, Choi, H, Kim, J, Yim, J et al. (2003). The nuclear RNase III Drosha initiates microRNA processing. Nature 425:415-419. (Pubitemid 37187272)
4. Gregory, RI, Yan, K P, Amuthan, G, Chendrimada, T, Doratotaj, B, Cooch, N et al. (2004). The Microprocessor complex mediates the genesis of microRNAs. Nature 432:235-240. (Pubitemid 39545855)
5. Schwarz, DS, Hutvágner, G, Du, T, Xu, Z, Aronin, N and Zamore, PD (2003). Asymmetry in the assembly of the RNAi enzyme complex. Cell 115:199-208. (Pubitemid 37329583)
6. Khvorova, A, Reynolds, A and Jayasena, SD (2003). Functional siRNAs and miRNAs exhibit strand bias. Cell 115:209-216. (Pubitemid 37329584)
7. Guo, H, Ingolia, NT, Weissman, JS and Bartel DP (2010). Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466:835-840.
8. Lewis, BP, Burge, CB and Bartel, DP (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15-20. (Pubitemid 40094598)
9. Davidson, BL and McCray, PB Jr (2011). Current prospects for RNA interference-based therapies. Nat Rev Genet 12:329-340.
10. Paul, CP, Good, PD, Winer, I and Engelke, DR (2002). Effective expression of small interfering RNA in human cells. Nat Biotechnol 20:505-508. (Pubitemid 34495939)
11. Zeng, Y, Wagner, EJ and Cullen, BR (2002). Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 9:1327-1333. (Pubitemid 34722311)
12. Chi, JT, Chang, HY, Wang, NN, Chang, DS, Dunphy, N and Brown, PO (2003). Genomewide view of gene silencing by small interfering RNAs. Proc Natl Acad Sci USA 100:6343-6346. (Pubitemid 36666583)
13. Semizarov, D, Frost, L, Sarthy, A, Kroeger, P, Halbert, DN and Fesik, SW (2003). Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci USA 100:6347-6352. (Pubitemid 36666584)
14. Jackson, AL, Bartz, SR, Schelter, J, Kobayashi, SV, Burchard, J, Mao, M et al. (2003). Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21:635-637. (Pubitemid 36638089)
15. Birmingham, A, Anderson, EM, Reynolds, A, Ilsley-Tyree, D, Leake, D, Fedorov, Y et al. (2006). 3' UTR seed matches, but not overall identity, are associated with RNAi offtargets. Nat Methods 3:199-204.
16. Fedorov, Y, Anderson, EM, Birmingham, A, Reynolds, A, Karpilow, J, Robinson, K et al. (2006). Off-target effects by siRNA can induce toxic phenotype. RNA 12:1188-1196. (Pubitemid 43990544)
17. Anderson, EM, Birmingham, A, Baskerville, S, Reynolds, A, Maksimova, E, Leake, D et al. (2008). Experimental validation of the importance of seed complement frequency to siRNA specificity. RNA 14:853-861. (Pubitemid 351574907)
18. Birmingham, A, Anderson, E, Sullivan, K, Reynolds, A, Boese, Q, Leake, D et al. (2007). A protocol for designing siRNAs with high functionality and specificity. Nat Protoc 2:2068-2078. (Pubitemid 351565844)
19. Naito, Y, Yoshimura, J, Morishita, S and Ui-Tei, K (2009). siDirect 2.0: updated software for designing functional siRNA with reduced seed-dependent off-target effect. BMC Bioinformatics 10:392.
20. Jackson, AL and Linsley, PS (2010). Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9:57-67.
21. Ross, CA and Tabrizi, SJ (2011). Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10:83-98.
22. Harper, SQ, Staber, PD, He, X, Eliason, SL, Martins, IH, Mao, Q et al. (2005). RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 102:5820-5825. (Pubitemid 40559643)
23. Rodriguez-Lebron, E, Denovan-Wright, EM, Nash, K, Lewin, AS and Mandel, RJ (2005). Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther 12:618-633. (Pubitemid 41350143)
24. Franich, NR, Fitzsimons, HL, Fong, DM, Klugmann, M, During, MJ and Young, D (2008). AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol Ther 16:947-956. (Pubitemid 351587106)
25. Boudreau, RL, McBride, JL, Martins, I, Shen, S, Xing, Y, Carter, BJ et al. (2009). Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 17:1053-1063.
26. Drouet, V, Perrin, V, Hassig, R, Dufour, N, Auregan, G, Alves, S et al. (2009). Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 65:276-285.
27. Boudreau, RL, Monteys, AM and Davidson, BL (2008). Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA 14:1834-1844.
28. McBride, JL, Boudreau, RL, Harper, SQ, Staber, PD, Monteys, AM, Martins, I et al. (2008). Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 105:5868-5873. (Pubitemid 351758464)
29. Boudreau, RL, Martins, I and Davidson, BL (2009). Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther 17:169-175.
30. Matveeva, O, Nechipurenko, Y, Rossi, L, Moore, B, Saetrom, P, Ogurtsov, AY et al. (2007). Comparison of approaches for rational siRNA design leading to a new efficient and transparent method. Nucleic Acids Res 35:e63.
31. Huesken, D, Lange, J, Mickanin, C, Weiler, J, Asselbergs, F, Warner, J et al. (2005). Design of a genome-wide siRNA library using an artificial neural network. Nat Biotechnol 23:995-1001. (Pubitemid 41114034)
32. Grimson, A, Farh, KK, Johnston, WK, Garrett-Engele, P, Lim, LP and Bartel, DP (2007). MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27:91-105. (Pubitemid 46991392)
33. Grimm, D, Streetz, KL, Jopling, CL, Storm, TA, Pandey, K, Davis CR et al. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537-541. (Pubitemid 44050158)
34. Huang, C, Li, M, Chen, C and Yao, Q (2008). Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 12:637-645. (Pubitemid 351699481)
35. Burchard, J, Jackson, AL, Malkov, V, Needham, RH, Tan, Y, Bartz, SR et al. (2009). MicroRNA-like off-target transcript regulation by siRNAs is species specific. RNA 15:308-315.
36. Jackson, AL, Burchard, J, Leake, D, Reynolds, A, Schelter, J, Guo, J et al. (2006). Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12:1197-1205. (Pubitemid 43990545)
37. Bramsen, JB, Pakula, MM, Hansen, TB, Bus, C, Langkjær, N, Odadzic, D et al. (2010). A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res 38:5761-5773.
38. Vaish, N, Chen, F, Seth, S, Fosnaugh, K, Liu, Y, Adami, R et al. (2011). Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs. Nucleic Acids Res 39:1823-1832.
39. Urabe, M, Ding, C and Kotin, RM (2002). Insect cells as a factory to produce adenoassociated virus type 2 vectors. Hum Gene Ther 13:1935-1943. (Pubitemid 35341035)
40. Huang da, W, Sherman, BT, Tan, Q, Collins, JR, Alvord, WG, Roayaei, J et al. (2007). The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 8:R183.
41. Halperin, Y, Linhart, C, Ulitsky, I and Shamir, R (2009). Allegro: analyzing expression and sequence in concert to discover regulatory programs. Nucleic Acids Res 37:1566-1579.